Show simple item record

dc.contributor.authorKaddu-Mulindwa, Dominic
dc.contributor.authorKeuser, Lukas
dc.contributor.authorLesan, Vadim
dc.contributor.authorRissland, Jürgen
dc.contributor.authorSmola, Sigrun
dc.contributor.authorWerdecker, Victoria
dc.contributor.authorStilgenbauer, Stephan
dc.contributor.authorChristofyllakis, Konstantinos
dc.contributor.authorThurner, Lorenz
dc.contributor.authorBewarder, Moritz
dc.contributor.authorLohr, Benedikt
dc.contributor.authorLutz, Jens
dc.contributor.authorLohse, Stefan
dc.contributor.authorRieke, Ansgar
dc.date.accessioned2022-01-18T14:23:38Z
dc.date.available2022-01-18T14:23:38Z
dc.date.issued2021-11-22
dc.identifier.citationHIV Med. 2021 Nov 22. doi: 10.1111/hiv.13207. Epub ahead of print.en_US
dc.identifier.pmid34811869
dc.identifier.doi10.1111/hiv.13207
dc.identifier.urihttp://hdl.handle.net/10033/623147
dc.description.abstractObjectives: Seroprevalence studies of SARS-CoV-2 have shown that there is a high number of undiagnosed missing cases. Seroprevalence of SARS-CoV-2 in people living with HIV (PLWH) is lacking. Therefore, we conducted a prospective cross-sectional study to estimate the seroprevalence of SARS-CoV-2 among PLWH without known diagnosis of COVID-19 in the south-west of Germany. Methods: Serological testing for SARS-CoV-2 immunoglobulin G (IgG) antibodies based on two assays was performed in PLWH who visited the outpatient HIV centre of two hospitals from April to June 2020. Additionally, patients had to answer questionnaires about possible COVID-19-related symptoms and predefined risk factors. Moreover, we tested 50 non-HIV-infected patients receiving post- or pre-exposure (PEP/PrEP) HIV prophylaxis. Results: In all, 594 (488 male, 106 female) PLWH (median age 51 years) and 50 PEP/PrEP-users were included in the study. The estimated seroprevalence of the PLWH cohort was 1.85% (11/594), with 11 positive tested cases in the cohort. Among all patients, only five had COVID-19-related symptoms. One PCR-positive patient did not show any antibody response in repeatedly carried out tests. None of the patients was hospitalized due to COVID-19. Three PrEP users were tested positive. Three patients had been previously diagnosed with SARS-COV-2 infection before inclusion. The used questionnaire did not help to detect SARS-CoV-2 positive patients.en_US
dc.language.isoenen_US
dc.publisherJohn Wiley & Sons LTDen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCOVID-19en_US
dc.subjectHIVen_US
dc.subjectSARS-CoV-2en_US
dc.subjectantibodyen_US
dc.subjectseroprevalenceen_US
dc.titleIgG seroprevalence of COVID-19 among people living with HIV or at high risk of HIV in south-west Germany: A seroprevalence study.en_US
dc.typeArticleen_US
dc.identifier.eissn1468-1293
dc.contributor.departmentHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalHIV medicineen_US
refterms.dateFOA2022-01-18T14:23:38Z
dc.source.journaltitleHIV medicine
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Kaddu- Mulindwa et al.pdf
Size:
78.21Kb
Format:
PDF
Description:
Open Access publication
Thumbnail
Name:
Kaddu-Mindwa_suppl_Table.pdf
Size:
68.43Kb
Format:
PDF
Description:
supplemental Table 1

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International